IP Library Granted Patent US 8,420,368
Granted Patent B2
US 8,420,368 · App. 13/371,082 · Granted Apr 16, 2013

Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,420,368
App. No.
13/371,082
Granted
Apr 16, 2013
Kind
B2
Abstract

This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.

Claims (10)

1. A method for measuring the activity of a recombinant human arylsulfatase B (ARSB) to degrade dermatan sulfate (DS) substrates, comprising:

(a) culturing an isolated human cell deficient in the ARSB under conditions in which DS substrates for the ARSB accumulate;

(b) contacting the cell with the ARSB;

(c) lysing the cell;

(d) adding to the cell lysate an enzyme that (i) is specific for DS substrates and (ii) cleaves small oligosaccharides from the DS substrates;

(e) labeling the small oligosaccharides with a detectable moiety;

(f) optionally separating the labeled small oligosaccharides;

(g) detecting the labeled small oligosaccharides; and

(h) determining the activity of the ARSB to degrade DS substrates by comparing (i) the amount of labeled small oligosaccharides from cells contacted with the ARSB with (ii) the amount of labeled small oligosaccharides from cells not contacted with the ARSB, wherein a reduction in (h)(i) as compared to (h)(ii) indicates the activity of the ARSB to degrade DS substrates.

2. The method of claim 1 , wherein the enzyme in step (d) is chondroitin ABC lyase, and the small oligosaccharides in step (d) are DS disaccharides.

Assignments (3)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ADD INVENTOR NAME PREVIOUSLY RECORDED ON REEL 028038 FRAME 0035. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 4, 2013
From: VELLARD, MICHEL C.; KOPPAKA, VISH; DVORAK-EWELL, MELITA; PUNGOR, ERNO; HAGUE, CHARLES; CHEN, ZHI
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 029746/0625 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2012
From: VELLARD, MICHEL C.; KOPPAKA, VISH; DVORAK-EWELL, MELITA; PUNGOR, ERNO; HAGUE, CHARLES
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 028038/0035 →